#1 Clinical Trials Search in Europe

Sphingomyelin (Egg)

This article discusses the ongoing clinical trials investigating the use of CAL02, a drug containing Sphingomyelin (Egg) and Cholesterol, for treating severe community-acquired bacterial pneumonia (SCABP). The study aims to evaluate the efficacy, safety, and tolerability of CAL02 when administered intravenously alongside standard care in patients with SCABP.

Table of Contents

What is CAL02?

CAL02 is an investigational medication being studied for the treatment of severe community-acquired bacterial pneumonia (SCABP). It is a solution for intravenous infusion, which means it is given directly into the bloodstream through a vein[1]. The active substances in CAL02 are cholesterol and sphingomyelin (egg), which are naturally occurring compounds in the body[1].

Target Condition: Severe Community-Acquired Bacterial Pneumonia (SCABP)

Severe community-acquired bacterial pneumonia (SCABP) is a serious lung infection that develops outside of hospitals or healthcare facilities. It is caused by bacteria and can lead to severe respiratory problems and other complications[1]. Patients with SCABP often require critical care management and may need assistance with breathing.

How CAL02 Works

While the exact mechanism of action is not fully explained in the provided information, CAL02 is designed to be administered intravenously in addition to standard care for patients with SCABP. The combination of cholesterol and sphingomyelin may have properties that help combat the severe bacterial infection and its effects on the body[1].

Clinical Trial Details

A Phase 2 clinical trial is being conducted to evaluate the efficacy, safety, and tolerability of CAL02 in patients with SCABP. This study is described as a randomized, double-blind, placebo-controlled multicenter study[1]. Here’s what these terms mean for patients:

  • Randomized: Participants are randomly assigned to either receive CAL02 or a placebo.
  • Double-blind: Neither the patients nor the doctors know who is receiving CAL02 or the placebo.
  • Placebo-controlled: Some participants will receive an inactive substance (placebo) instead of CAL02 to compare the effects.
  • Multicenter: The study is conducted at multiple hospitals or medical centers.

Eligibility Criteria

To participate in the CAL02 clinical trial, patients must meet specific criteria. Some key inclusion criteria include[1]:

  • Age 18 years or older
  • Body weight between 40 to 140 kg (88 to 308 lb)
  • Diagnosed with CABP within 48 hours of hospital admission
  • Meeting specific severity criteria, such as requiring mechanical ventilation or having septic shock

There are also several exclusion criteria, which means patients with certain conditions or circumstances cannot participate in the trial. These include[1]:

  • Having other types of pneumonia (e.g., ventilator-associated, aspiration, or hospital-acquired)
  • Severe kidney problems
  • Known hypersensitivity to egg or egg components
  • Certain medical conditions that might interfere with the study results

Potential Benefits of CAL02

The clinical trial aims to evaluate several potential benefits of CAL02, including[1]:

  • Faster clinical recovery compared to placebo
  • Reduced duration of critical care management
  • Shorter overall hospital stay
  • Improved early clinical recovery (by Day 5)
  • Positive effects on SOFA scores (Sequential Organ Failure Assessment, a scoring system used to determine the extent of organ dysfunction)

Safety Considerations

As with any investigational medication, safety is a crucial aspect of the CAL02 clinical trial. The study will closely monitor[1]:

  • The incidence and severity of treatment-emergent adverse events (TEAEs), including infusion-related reactions
  • Any interruptions or discontinuations of the CAL02 infusion

It’s important to note that CAL02 contains egg-derived components, so patients with known hypersensitivity to egg or egg components are not eligible for the trial[1].

Aspect Details
Study Type Phase 2, randomized, double-blind, placebo-controlled multicenter study
Drug CAL02 (containing Sphingomyelin (Egg) and Cholesterol)
Condition Severe Community-Acquired Bacterial Pneumonia (SCABP)
Primary Endpoints Time to clinical recovery, incidence and severity of treatment-emergent adverse events, incidence of infusion interruptions and discontinuations
Key Inclusion Criteria Adults ≥18 years, 40-140 kg weight, CABP diagnosis, specific severity criteria, requiring critical care
Key Exclusion Criteria Other types of pneumonia, refractory septic shock, severe renal impairment, hypersensitivity to egg components
Administration Intravenous infusion, max daily dose 1920 mg, max total dose 3840 mg over 2 days

FAQ

  • What is CAL02 and what is it being studied for? CAL02 is a drug containing Sphingomyelin (Egg) and Cholesterol. It is being studied as a potential treatment for severe community-acquired bacterial pneumonia (SCABP) when administered intravenously along with standard care.
  • Who can participate in this clinical trial? Participants must be 18 years or older, weigh between 40 to 140 kg, have a clinical diagnosis of CABP, and meet specific severity criteria. They must also require critical care for managing SCABP and provide informed consent.
  • What are the main objectives of the study? The main objectives are to evaluate the effect of CAL02 on clinical recovery compared to placebo, and to assess its safety and tolerability. Secondary objectives include evaluating its impact on the duration of critical care management and overall hospital stay.
  • How is CAL02 administered in the trial? CAL02 is administered as an intravenous infusion. The maximum daily dose is 1920 mg, with a maximum total dose of 3840 mg over a 2-day treatment period.
  • What are some key exclusion criteria for the trial? Key exclusions include having ventilator-associated pneumonia, aspiration pneumonia, hospital-acquired pneumonia, severe renal impairment, known hypersensitivity to egg or egg components, and participation in other recent investigational studies.

Ongoing Clinical Trials on Sphingomyelin (Egg)

  • Study on CAL02 and Sodium Chloride for Patients with Severe Community-Acquired Bacterial Pneumonia

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Belgium Czechia France Greece Hungary Latvia +3

Glossary

  • SCABP: Severe Community-Acquired Bacterial Pneumonia, a serious lung infection caused by bacteria acquired outside of healthcare settings.
  • Sphingomyelin: A type of fat (lipid) found in cell membranes, particularly in the myelin sheath that surrounds nerve cells.
  • Intravenous infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • SOFA score: Sequential Organ Failure Assessment score, used to track a patient's status during their stay in an intensive care unit.
  • PaO2/FiO2 ratio: A measure of the oxygen level in the blood compared to the amount of oxygen being given to the patient, used to assess lung function.
  • Vasopressors: Medications that constrict blood vessels to increase blood pressure in patients with severe infections or shock.
  • Septic shock: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ failure.

References

  1. http://clinicaltrials.eu/trial/study-on-cal02-and-sodium-chloride-for-patients-with-severe-community-acquired-bacterial-pneumonia/